45th week of 2014 patent applcation highlights part 32 |
Patent application number | Title | Published |
20140328828 | USE OF THERAPEUTIC COMPOSITIONS COMPRISING HYALURONAN AND THERAPEUTIC ANTIBODIES - The present invention relates generally to treatment and prophylactic protocols for cellular disease or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides uses of compositions comprising therapeutic antibodies and hyaluronan in the treatment or prophylaxis of cellular diseases and disorders. | 2014-11-06 |
20140328829 | AGR2 BLOCKING ANTIBODY AND USE THEREOF - Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis. | 2014-11-06 |
20140328830 | ANTI-INTEGRIN BETA-1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF - The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin β1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer. | 2014-11-06 |
20140328831 | SINGLE DOMAIN TDF-RELATED COMPOUNDS AND ANALOGS THEREOF - The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders. | 2014-11-06 |
20140328832 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY - Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a substituted quinazolinone compound and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer. | 2014-11-06 |
20140328833 | METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually. | 2014-11-06 |
20140328834 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR - A pharmaceutical combination comprising an Hsp90 inhibitor and an HER2 inhibitor, and methods of using the combination to treat proliferative disorders. | 2014-11-06 |
20140328835 | METHODS FOR TREATING RETINOPATHY WITH EXTENDED THERAPEUTIC EFFECT - Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy. | 2014-11-06 |
20140328836 | HER2/neu-Specific Antibodies and Methods of Using Same - This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease. | 2014-11-06 |
20140328837 | Affinity Peptides Toward Infliximab - We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab. | 2014-11-06 |
20140328838 | CANINISED ANTIBODIES AND METHOD FOR PRODUCTION OF SAME - A method of producing a non-immunogenic immunoglobulin for administration to a target species is provided wherein the method comprises substituting amino acid residues in framework regions of a donor immunoglobulin with amino acid residues present at a corresponding position in framework regions of at least one immunoglobulin derived from the target species. Also provided are antibodies produced by the method of the invention, including novel humanised and caninised anti-NGF antibodies. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a human or dog using said antibodies and/or nucleic acids. | 2014-11-06 |
20140328839 | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma - Provided herein is are methods of reducing the number and severity of acute exacerbations of asthma in an asthma patient, comprising administering to a patient with a history of acute exacerbations of asthma an effective amount of an anti-interleukin-5 receptor (IL-5R) antibody or antigen-binding fragment thereof, for example, an anti-IL-5Rα antibody or antigen-binding fragment thereof, e.g., benralizumab. | 2014-11-06 |
20140328840 | MARKER AND TARGET FOR RESPONSIVENESS AND RESISTANCE TO CANCER AGENTS - An assay of identifying the responsiveness of a HER2-positive cancer in a patient to a HER2 targeted drug, the method comprising the step of comparing a level of NeuromedinU in a biological sample obtained from the patient with a reference level of NeuromedinU, wherein detection of a level of NeuromedinU that is increased compared to the reference level of NeuromedinU indicates that the HER2-positive cancer has reduced responsiveness to a HER2 targeted drug. | 2014-11-06 |
20140328841 | ANTI-CEACAM1 RECOMBINANT ANTIBODIES FOR CANCER THERAPY - Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer. | 2014-11-06 |
20140328842 | Predicting Responsiveness to Antibody Maintenance Therapy - Methods, reagents and kits are provided for predicting whether an individual suffering from an antibody dependent cell-mediated cytotoxicity (ADCC)-treatable disease is responsive to an antibody maintenance therapy. The methods, reagents, and kits find a number of uses, including, for selecting individuals who will be responsive for treatment with an antibody maintenance therapy, for determining the appropriate maintenance therapy for an individual suffering from an ADCC-treatable disease, for determining the optimal regimen for antibody maintenance therapy, and for treating an individual with an antibody maintenance therapy based on stratification into responsive groups. | 2014-11-06 |
20140328843 | Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof - The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies bind FcγRIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-FcγRIIB antibody and an anti-CD20 antibody. | 2014-11-06 |
20140328844 | METHODS OF USE FOR TACI-IMMUNOGLOBULIN FUSION PROTEINS - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors. | 2014-11-06 |
20140328845 | METHODS FOR INCREASING THERMOGENIC ADIPOCYTES - In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes. | 2014-11-06 |
20140328846 | ANTI-PROPERDIN ANTIBODIES - A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject. | 2014-11-06 |
20140328847 | MITIGATION OF DISEASE BY INHIBITION OF GALECTIN-12 - It has now been discovered that mice with an ablated galectin-12 gene exhibit enhanced fat mobilization (lipolysis), have reduced adipose tissue mass, improved insulin sensitivity and glucose tolerance, and increased mitochondrial respiration. Inhibition of galectin-12 activity can therefore be used to reduce, mitigate, inhibit and/or prevent obesity, type 2 diabetes, metabolic diseases, mitochondrial diseases, other disease conditions associated with and/or caused by the abnormal expression or overexpression of galectin-12, and other disease conditions with normal galectin-12 expression but will benefit from galectin-12 inhibition. | 2014-11-06 |
20140328848 | Method for Treating Metabolic Disorders - The present invention relates to compositions comprising anti-ActRIIB antibodies and use thereof for increasing brown fat in vertebrate, including rodents and primates, and particularly in humans without significantly affecting hematological parameters. | 2014-11-06 |
20140328849 | ANTI-CRTH2 ANTIBODIES AND METHODS OF USE - The invention provides anti-CRTh2 antibodies and methods of using the same. | 2014-11-06 |
20140328850 | APELIN ANTIGEN-BINDING PROTEINS AND USES THEREOF - This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications. | 2014-11-06 |
20140328851 | Cholesterol Ester Transfer Protein (CETP) Inhibitor Polypeptide Antibodies for Prophylactic and Therapeutic Anti-Atherosclerosis Treatments - Herein are described two antibodies that can inhibit CETP-lipoproteins interaction and CETP activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the N-terminal or C-terminal domains of CETP and methods of using these antibodies for separation, identification, diagnosis and therapy. | 2014-11-06 |
20140328852 | IMMUNOGENIC GLUTEN PEPTIDES AND USES THEREOF - The invention relates to an immunogenic peptide of eight amino acids that is generated naturally in the intestine of celiac patients by means of the hydrolysis of ingested gluten. In addition, the invention relates to the use of the peptide, or antibodies generated against same, for the in vitro monitoring and/or diagnosis of celiac disease, as well as to the use of such antibodies for the detection of gluten in food. The invention further relates to the use of the aforementioned peptide as a therapeutic target for the development of compounds or compositions for use in the diagnosis, treatment and/or prevention of this pathological condition, as well as to the use of the peptide and the antibodies against same for the prevention and/or treatment of celiac disease. | 2014-11-06 |
20140328853 | ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR PREVENTION OR REDUCTION OF ORGAN DYSFUNCTION OR ORGAN FAILURE IN A PATIENT HAVING A CHRONIC OR ACUTE DISEASE OR ACUTE CONDITION - Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure. | 2014-11-06 |
20140328854 | TOLEROGENIC SYNTHETIC NANOCARRIERS AND THERAPEUTIC MACROMOLECULES FOR REDUCED OR ENHANCED PHARMACODYNAMIC EFFECTS - Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions. | 2014-11-06 |
20140328855 | METHOD OF TREATING ANKYLOSING SPONDYLITIS - The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject. | 2014-11-06 |
20140328856 | TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G - The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg/kg to 800 mg/kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and/or an anti-beta amyloid monoclonal antibody. | 2014-11-06 |
20140328857 | Novel B7-H3L Cell Surface Antigen and Antibodies That Bind Thereto - The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10. | 2014-11-06 |
20140328858 | LIN28-MEDIATED CONTROL OF LET-7 BIOGENESIS - The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3′ terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA. | 2014-11-06 |
20140328859 | ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES - The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of β-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing. | 2014-11-06 |
20140328860 | METHODS FOR STIMULATING HEMATOPOIETIC RECOVERY BY INHIBITING TGF BETA SIGNALING - This disclosure demonstrates that blockade of TGFβ signaling after a hematopoietic stress (e.g., chemotherapy, transplantation, and infection) accelerates hematopoietic reconstitution and delays the return of cycling hematopoietic stem and progenitor cells (HSPCs) to quiescence. TGFβ blockade in these settings promotes multilineage hematopoietic regeneration by prolonging HSPC cycling and by promoting HSC self-renewal, and is useful for treating hematologic deficiencies caused various hematopoietic stresses. | 2014-11-06 |
20140328861 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis - Disclosed are methods and compositions for preventing, treating, or ameliorating eosinophilic esophagitis (EoE) in an individual, comprising administering to the individual a therapeutically effective amount of at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor (PPI) or a pharmaceutically acceptable salt thereof. Also disclosed are compositions comprising at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor or a pharmaceutically acceptable salt thereof. | 2014-11-06 |
20140328862 | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF - The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection. | 2014-11-06 |
20140328863 | Induction of Differential Stress Resistance and Uses Thereof - This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents. | 2014-11-06 |
20140328864 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING AIRWAY HYPERRESPONSE - The present invention relates to agent selected from the group consisting of an anti-S100B antibody, an anti-S100B aptamer or an inhibitor of S100B gene expression for use in a method for reducing airway hyperresponse in a subject in need thereof. The present invention also relates to a method for determining whether a subject is at risk of having or developing an airway hyperresonse comprising determining the level of S100B protein in a biological sample obtained from said subject. | 2014-11-06 |
20140328865 | Immune Modulation Via C-Type Lectin - The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved. | 2014-11-06 |
20140328866 | Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier - The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents. | 2014-11-06 |
20140328867 | MICROWAVE VACUUM-DRYING OF ORGANIC MATERIALS - An apparatus ( | 2014-11-06 |
20140328868 | T-CELL ANTIGEN PEPTIDE FROM ALLERGEN FOR STIMULATION OF IL-10 PRODUCTION - A first or second polypeptide for use in a method of treating or preventing a disorder by tolerisation, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides:
| 2014-11-06 |
20140328869 | METHODS FOR IMPROVING THE DESIGN, BIOAVAILABILITY, AND EFFICACY OF RANDOM SEQUENCE POLYMER COMPOSITIONS VIA SERUM PROTEIN-BASED DETECTION OF RANDOM SEQUENCE POLYMER COMPOSITIONS - There exist in the art methods of detecting simple peptides. However, methods to determine the effective plasma concentration of mixtures of peptides as a group, rather than for individual peptides with a defined amino acid sequence, are complicated by the heterogeneity of the peptides to be detected. This application provides improved methods of detecting and assessing random sequence polymer (RSP) compositions, methods for the detection and quantitation of RSP compositions, means to determine and enrich a subset of peptides in an RSP composition based on the subset's interactions with certain capture polypeptides, and methods for administering RSP compositions to a subject in need thereof, wherein the dosage regimen and quantity may be determined or evaluated based on the above-mentioned methods for detection and quantitation. | 2014-11-06 |
20140328870 | NUCLEIC ACID VACCINES AGAINST HERPES SIMPLEX VIRUS TYPE 2: COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE - Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically. | 2014-11-06 |
20140328871 | Method of Culturing Antrodia cinnamomea, a method of manufacturing an alcoholic extract of Antrodia cinnamomea and a medication of suppressing viability of tumor cells - A method of culturing | 2014-11-06 |
20140328872 | Formula of Suppressing Viability of Tumor Cells and a Medication Thereof - A formula of suppressing viability of tumor cells is disclosed. The formula comprises 27.3-50.0 wt % of | 2014-11-06 |
20140328873 | Norovirus Immunogens and Related Materials and Methods - The inventors have successfully developed a recombinant vesicular stomatitis virus which expresses the major capsid protein of human norovirus. Infection of mammalian cells with the recombinant vesicular stomatitis virus resulted in production of high level of human norovirus virus-like particles. Importantly, the inventors further demonstrated that recombinant vesicular stomatitis virus expressing the major capsid protein of human norovirus displayed attenuated virulence in mice and elicited a high level of human norovirus-specific humoral, cellular, and mucosal immune responses in mice model. Therefore, norovirus-immunogenic compositions are herein provided, as are materials and methods useful to make and use the compositions. | 2014-11-06 |
20140328874 | SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION - To overcome the limitations of existing particle quantification techniques, the inventors used disc centrifugation in combination with a detector, to quantify particles, in particular virus particles. Also provided is a method for determining particle density using a disc centrifuge. This method is particularly useful for determining virus particle density. Also provided is a method of estimating particle size, based on particle density. | 2014-11-06 |
20140328875 | INFLUENZA VIRUS VACCINES AND USES THEREOF - Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use. | 2014-11-06 |
20140328876 | SYNTHETIC DERIVATIVES OF MPL AND USES THEREOF - In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly. | 2014-11-06 |
20140328877 | WEST NILE VIRUS VACCINE - The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates. | 2014-11-06 |
20140328878 | MALLEABLE PROTEIN MATRIX AND USES THEREOF - The present invention relates to a malleable protein matrix (MPM), which is the reaction product of the agglomeration of proteins after a fermentation process and is exhibiting biological activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophylic substances. The present invention also relates to the process for the preparation of the malleable protein matrix and its usages. | 2014-11-06 |
20140328879 | PROBIOTIC BIFIDOBACTERIUM STRAINS | 2014-11-06 |
20140328880 | Modified Pathogens For Use As Vaccines - Described herein are microorganisms that are modified so that they have an increased ability to be recognized by the innate immune system of a eukaryote, relative to an unmodified microorganism. A microorganism may be a gram-negative bacterium that has been modified to produce high potency lipopolysaccharide, e.g., | 2014-11-06 |
20140328881 | HYPOALLERGENIC VARIANTS OF PHL P 5, THE MAJOR ALLERGEN FROM PHLEUM PRATENSE - Disclosed are hypoallergenic variants of PhI p 5, the major allergen from | 2014-11-06 |
20140328882 | WHEAT GERM EXTRACT OBTAINED BY PROTEASE HYDROLYSIS AND MEDICAL USE THEREOF - The invention relates to a dried enzymically hydrolyzed plant material, which is capable of immunmodulation, immunoregulation, reducing inflammation and reducing tumor progression. The material can be used in the manufacture of pharmaceutical compositions, dietary supplements, dietary foods for medical purposes, nutraceuticals, in feed materials, and in supplementary feeds. The process for producing the material is also described, as are its use in the modulation, and regulation of immune reactions, reducing inflammation and/or tumor progression. The material can also be used in treatment of several inflammatory disorders. | 2014-11-06 |
20140328883 | METHOD FOR PREPARING CROSSLINKED POLYELECTROLYTE MULTILAYER FILMS - The invention relates to methods for preparing crosslinked polyelectrolytes, in particular crosslinked polyelectrolytes multilayer films. The invention also relates to a method of coating a surface, and the obtained coated article. | 2014-11-06 |
20140328884 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES - Controlled release vehicles may include a polymeric matrix that comprises the polymeric matrix comprising at least one selected from the group consisting of an ethylene copolymer, an ethyl cellulose, a thermoplastic polyurethane, any partially crosslinked polymer thereof, and any combination thereof and has a desired void space architecture. | 2014-11-06 |
20140328885 | SHEET FOR CUTANEOUS APPLICATION CONTAINING VITAMIN E OR AN ESTER THEREOF - Sheet for cutaneous application comprising a support layer made of loosely woven fabric embedded in a layer of silicone elastomer incorporating vitamin E or an ester thereof, wherein the layer of silicone elastomer has a thickness less than or equal to 2.0 mm and the silicone elastomer contains an elasticity modifier consisting of a triglyceride of saturated C | 2014-11-06 |
20140328886 | INSECT PEST REPELLANT (AS AMENDED) - The present invention provides an insect pest repellant and a method for repelling insect pest using the same, which is highly transported by the insect pests and which effectively exterminates insect pests and does not badly affect ecological system. The present invention is to provide an insect pest repellant comprising, in a mixed condition, (A) a dummy egg imitating an egg of an insect pest, formed from a particulate substrate on which an egg recognizing pheromone is coated, and (B) a particle containing an active component for repelling the insect pest either on a surface or in an inside of the particle. | 2014-11-06 |
20140328887 | Family of Silver (I) Periodate Compounds Having Broad Microbial Properties - The present application discloses a method of making a surface antimicrobial by coating or forming a surface with a silver (I) periodate as well as articles of manufacture comprising a silver (I) periodate. The present application also discloses a method of preventing or reducing microbial contamination on a substrate by coating the substrate with at least one silver (I) periodate. The substrate can be a wound dressing, a medical instrument, a medical device, a metallic article, a plant or a seed. | 2014-11-06 |
20140328888 | Swellable fiber and microfiber forming polyether-esters and applications thereof - Biomedical and tissue engineering devices, such as surgical sutures and microporous scaffolds, respectively, which undergo swelling and increase in dimensions when placed in aqueous environments such as living tissues, are produced by the melt-spinning or electrostatic spinning into strong monofilament and multifilament yarns or microfibrous fabrics, respectively. Such devices are formed from especially high molecular weight crystalline polyether-esters having a minimum inherent viscosity of 0.8 dL/g and heat of fusion of at least 5 J/g, wherein the polyether-esters are made by grafting to a polyester component a polyether glycol component having a minimum molecular weight of about 11 kDa with at least one cyclic monomer. | 2014-11-06 |
20140328889 | METHOD FOR PRODUCING RUTILE TYPE TITANIUM OXIDE SOL - There is provided provide a method for efficiently producing a rutile type titanium sol having a particle diameter based on dynamic light scattering method of 5 nm to 100 nm that is excellent in dispersibility. The method for producing a rutile type titanium oxide sol comprising: process (a): mixing metastannic acid, a titanium alkoxide, a quaternary ammonium hydroxide, oxalic acid, and water so as to contain 0.02 moles to 0.8 moles of tin atoms, 0.1 moles to 3.5 moles of the quaternary ammonium hydroxide, and 0.1 moles to 8.0 moles of the oxalic acid with respect to 1 mole of titanium atoms of the titanium alkoxide to prepare a titanium-containing aqueous solution with a concentration in terms of TiO | 2014-11-06 |
20140328890 | Silver Iodate Compounds Having Antimicrobial Properties - The present invention is compositions, methods of use, methods of treating, and articles of manufacture that include at least one silver iodate for imparting antimicrobial properties, particularly as it relates to the manufacture, use, and properties of medical devices. The invention also includes obtaining and using one or more silver iodate reaction products from a diperiodatoargentate, wherein the reaction products are obtained using a hydrothermal reaction. | 2014-11-06 |
20140328891 | COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS - Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant. | 2014-11-06 |
20140328892 | USE OF ALFIMEPRASE IN THE TREATMENT OF THROMBOSIS - Methods for treatment of arterial or venous thrombosis in patients undergoing an endovascular intervention or a surgical procedure, and more particularly, administering alfimeprase directly into the thrombus or adjacent to the thrombus in a coronary, cerebral, or peripheral vessel. | 2014-11-06 |
20140328893 | NUTLIN COMPOUNDS FOR USE IN THE TREATMENT OF PULMONARY HYPERTENSION - The present invention relates to uses, methods and compositions for the treatment of pulmonary hypertension. | 2014-11-06 |
20140328894 | DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM - An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent. | 2014-11-06 |
20140328895 | FILM-FORMING COMPOSITION FOR A PH-DEPENDANT SUSTAINED RELEASE OF THE ACTIVE AGENT - The present invention discloses a liquid precursor composition adapted for application on a on a desired surface, this composition comprising: a. at least one therapeutic agent suitable for the treatment or prevention of a disorder or pathological condition, wherein said disorder or pathological condition excludes oral disorders, b. at least one acidic-pH sensitive polymer, c. at least one hydrophobic polymer, and d. a pharmaceutically acceptable volatile solvent, wherein a weight ratio between the at least one hydrophobic polymer and the at least one acidic-pH sensitive polymer is larger than 1. | 2014-11-06 |
20140328896 | COMPOSITIONS AND METHODS FOR MODIFYING GASTROINTESTINAL FLORA - Provided are methods and compositions for enhancing the gastrointestinal health of an animal in need thereof by administering a gastrointestinal health maintaining or improving amount of a composition comprising an effective amount of lactic acid. The administered composition may also comprise one or more prebiotic, probiotic, symbiotic, anti bacterial, or anti-diarrhea agents. | 2014-11-06 |
20140328897 | CHARGE TRIGGERING OF SELF-ORGANIZED NANOPARTICLES - The present application discloses a nanoparticle comprising compounds of the formula A-B-C(-D), wherein A designates an anchoring moiety having self-organizing properties in relation to the nanoparticle; B designates a cleavable linker; C designates an anionic moiety having a net charge of at least −2 at pH 6.0; and D, which is optional, designates a polymer moiety which induces long circulating properties of the nanoparticle in mammalian tissue; and wherein the average net charge of the compounds is at least −1 at pH 6.0. The application also discloses the individual compounds of the formula A-B-C(-D) as well as a drug delivery system comprising the self-organized nanoparticle having included in the interior thereof one or more pharmaceutically active agents and/or diagnostically relevant species, and a method of treating a cancerous or inflammatory condition in a mammal, involving the administration of the drug delivery system to the mammal. | 2014-11-06 |
20140328898 | Nano-Liposomal Formulations and Methods of Use - A method for transdermal drug delivery provides for the topical administration of liposome encapsulated nanoparticles. The encapsulated nanoparticles define a nearly monodisperse population of liposomes having an average diameter within a selected size range. Liposomal nanoparticle formulations and methods of treatment therewith are also provided. | 2014-11-06 |
20140328899 | LIPOSOMES CO-ENCAPSULATING A BISPHOSPHONATE AND AN AMPHIPATHIC AGENT - The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as γδ T-cells. | 2014-11-06 |
20140328900 | PROCESS FOR PREPARING HUMAN RELAXIN-2 - A process for preparing human relaxin-2 having the following amino acid sequence: | 2014-11-06 |
20140328901 | METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE - Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space. | 2014-11-06 |
20140328902 | ANTIMICROBIALS AND METHODS OF USE THEREOF FOR WOUND HEALING - This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth. | 2014-11-06 |
20140328903 | MEANS FOR INHIBITING THE EXPRESSION OF ANG2 - The present invention is related to an siRNA comprising an antisense strand and a sense strand, wherein all or a portion of said antisense strand comprises an antisense duplex region, wherein all or a portion of said sense strand comprises a sense duplex region, wherein said antisense duplex region is at least partially complementary to said sense duplex region, wherein said siRNA comprises a duplex region consisting of said antisense duplex region and said sense duplex region, and wherein: a) said antisense strand comprises a nucleotide sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 68, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102 or 104; or b) said antisense strand comprises an antisense duplex region, all or a portion of which, is complementary to a portion of SEQ ID NO: 1 or 70. | 2014-11-06 |
20140328904 | GLA MONOTHERAPY FOR USE IN CANCER TREATMENT - The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen. | 2014-11-06 |
20140328905 | METHODS AND COMPOSITIONS FOR X-RAY INDUCED RELEASE FROM PH SENSITIVE LIPOSOMES - Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure. | 2014-11-06 |
20140328906 | Methods of Treating Impaired Glucose Metabolism via Administration of Algal Biomass - The invention is directed to methods of using | 2014-11-06 |
20140328907 | ENTRAPMENT OF BIOACTIVES IN SOL-GEL ALUMINA MATERIALS - Provided is a platform for entrapment within alumina sol-gel carriers of labile biologically active materials such as proteins, therapeutic enzymes, enzymes of industrial relevance, antigens, and small molecules for achieving successful and efficient protective storage, protection from harsh environmental conditions such as heat, pH and chemicals, delivery to site and subsequent treatment and/or vaccination against diseases against which the active agents are targeted. | 2014-11-06 |
20140328908 | CONTROLLED-RELEASE FORMULATION - The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 μg/kg body weight/minute and 20 μg/kg body weight/minute. | 2014-11-06 |
20140328909 | KRILL OIL AND REACTED ASTAXANTHIN COMPOSITION AND ASSOCIATED METHOD - A method of treating and alleviating joint pain includes administering a therapeutic amount of a composition comprising krill oil reacted with astaxanthin. A medicine delivery system for the method and composition includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S′-astaxanthin derived from | 2014-11-06 |
20140328910 | INGESTION METHOD OF CREATINE COMPOSITION, CREATINE COMPOSITION FOR USING IN THE INGESTION METHOD, AND CREATINE-CONTAINING MEDICAMENT AND FOOD EACH PRODUCED USING THE CREATINE COMPOSITION - An ingestion method of creatine composition, taking orally the creatine composition with beverage, characterized in that, the creatine composition is taken orally by preparing creatine composition aqueous solution with dissolving the creatine composition over one minute into water heating at 80-100° C. and by mixing the creatine composition aqueous solution with the beverage having ordinary or cool temperature. | 2014-11-06 |
20140328912 | Delayed Release Tablet With Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 2014-11-06 |
20140328913 | RAPIDLY DISINTEGRATING GELATINOUS COATED TABLETS - The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms. | 2014-11-06 |
20140328914 | TALC-FREE POLYVINYL ALCOHOL COMPOSITION - The present invention provides a talc-free composition characterizable as non-tacky and having an average water vapor permeability of at most 5.0 times 10 | 2014-11-06 |
20140328915 | DOSAGE FORM FOR INSERTION INTO THE MOUTH - Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract. | 2014-11-06 |
20140328916 | 3-DIMENSIONAL CARDIAC FIBROBLAST DERIVED EXTRACELLULAR MATRIX - A bioscaffold made from an isolated cardiac fibroblast-derived 3-dimensional extracellular matrix (ECM) is disclosed. The bioscaffold can be used as an epicardial patch for the delivery of therapeutic cells into myocardial tissue. Methods of making the 3-dimensional extracellular matrix using cultured cardiac fibroblasts are also disclosed. | 2014-11-06 |
20140328917 | ORGANIC COMPOUND NANO-POWDER, METHOD FOR PRODUCING THE SAME AND SUSPENSION - An organic compound nano-powder comprising a granular organic compound with an average particle diameter of 500 nm or less and a 90%-diameter of less than 1500 nm and a carbohydrate compound comprising at least any one of a sugar and a sugar alcohol and with amount of 0.3 times or more by mass relative to amount of the organic compound, a method for producing the same, and a suspension having the organic compound dispersed in a liquid dispersion medium in which the organic compound is insoluble or poorly soluble. | 2014-11-06 |
20140328918 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS - Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates. | 2014-11-06 |
20140328919 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 2014-11-06 |
20140328920 | SYSTEM FOR THE DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS INTO AN ORGANISM AND METHOD FOR THE PREPARATION OF SAID SYSTEM - The invention relates to the field of pharmaceutics, pharmaceutical nano-technology and pharmacology and concerns a system for delivering biologically active agents into an organism, the system comprising a nano-diamond with a particle size of 2-10 nm, the surface of said particles being modified by chlorine with a chlorine content of up to 14%, and to a method for producing said system. | 2014-11-06 |
20140328921 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGEN - This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions. | 2014-11-06 |
20140328922 | LOCAL, CONCOMITANT ADMINISTRATION OF TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE TYPE I AND TYPE IV HYPERSENSITIVITY - Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity. | 2014-11-06 |
20140328923 | DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES - Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses. | 2014-11-06 |
20140328924 | DELIVERY OF IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE-LIFE AND ANTIGEN FOR THE INDUCTION OF IMMUNE TOLERANCE - This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule. | 2014-11-06 |
20140328925 | MICRONIZED TANAPROGET, COMPOSITIONS, AND METHODS OF PREPARING THE SAME - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 2014-11-06 |
20140328926 | MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS - The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses. | 2014-11-06 |
20140328927 | ANTI-CANCER NANOPARTICLE COMPOSITIONS AND METHODS OF USE - The present invention encompasses a composition capable of delivering and expressing a nucleic acid encoding UDP-Glucuronosyltransferases, p53 or a combination thereof into a cell, and methods for treating tumors. | 2014-11-06 |
20140328928 | Stable Aqueous Suspension - An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension. | 2014-11-06 |